Skip to main content
. 2022 Jan 22;14(3):553. doi: 10.3390/cancers14030553

Table 2.

Overview of completed clinical trials testing telaglenastat (CB-839) in various cancer patients.

Cancer Type Treatment Outcome Reference
Triple-negative breast cancer (TNBC) In combination with paclitaxel (chemotherapeutic agent targeting microtubules) In heavily pretreated patients with previous taxane exposure, the treatment demonstrated clinical activity and was well tolerated. [172]
Clear cell renal cell carcinoma (ccRCC), melanoma; non-small-cell lung cancer (NSCLC) In combination with nivolumab (immunotherapy medication targeting programmed cell death (PD-1) receptor) CB-839 was well tolerated when combined with nivolumab in melanoma, ccRCC, and NSCLC
patients.
[173]
Solid tumors with K-Ras mutation In combination with palbociclib (kinase inhibitor targeting cyclin-dependent kinases CDK4 and CDK6) NA NA
Solid tumors As a single agent and in combination with standard chemotherapy Acceptable safety profile under continuous CB-839 administration. Treatment resulted in glutaminase inhibition and clinical activity. [174]
Hematological tumors As a single agent or in combination with pomalidomide (immunomodulatory agent), dexamethasone (glucocorticoid), or pomalidomide and dexamethasone CB-839 administration was well tolerated and resulted in GLS inhibition in blood platelets and in tumors. Observed reductions in marrow and peripheral blast counts suggested clinical relevance. [175]
Renal cell carcinoma (RCC) In combination with cabozantinib (tyrosine kinase inhibitor) Did not achieve primary endpoint. [176]
ccRCC In combination with everolimus (mammalian target of rapamycin (mTOR) kinase inhibitor) In combination with everolimus, CB-839 demonstrated a tolerable safety profile. Modest (3.8 months from 1.9 months) progression-free survival was observed. [177]
Leukemia CB-839 as a single agent or in combination with azacitidine (chemotherapeutic agent, antimetabolite) CB-839 was well tolerated in advanced leukemia and resulted in GLS inhibition in platelets and PBMCs.
Two patients achieved significant reductions in blast counts.
[175]